The Atomo (ASX:AT1) share price has shot up 9%. Here's why

The diagnostics company released its fourth-quarter business update today.

| More on:
a man sits on a rocket propelled office chair and flies high above a city

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Atomo Diagnostics Ltd (ASX: AT1) share price has rocketed in opening trade today after the medical device company released its fourth-quarter results to the ASX.

At the time of writing, the Atomo share price is trading 9.30% higher at 23.5 cents apiece.

How did Atomo perform for the quarter?

The Atomo share price is soaring after the company reported a robust performance during the fourth quarter.

For the period ending 30 June, Atomo recorded cash receipts from customers of $717,000, bringing the full-year to $8.01 million. It's worth noting that shortly after the close of Q4 FY21, a further $750,000 was received.

Sales represented a total of $6.7 million for the 2021 financial year, up by 25% when compared to FY20 ($5.4 million).

Atomo ended the quarter with a cash balance of $17.95 million.

Pleasingly, the company is expecting sales to expand rapidly in FY22, with key multi-year agreements secured with Viatris and Unitaid. HIV self-testing kits – designed and manufactured by Atomo – will be sent to 135 low and middle-income countries.

During late in the fourth quarter, the company received an initial order of 250,000 units under the Unitaid purchasing program. These products have since been shipped and delivered, with the majority of the order to be fulfilled in Q1 FY22.

To support the large order and potential future orders, Atomo has expanded operations at its South African facility. This includes additional assembly and packaging lines, as well as hiring and training further staff.

Across in the United States market, Atomo revealed that discussions with Access Bio were ongoing in relation to delivering its COVID-19 antibody test kits. Previously, Access Bio ordered 260,000 devices from Atomo, in part of the take-or-pay commitment of 2 million units by 30 September.

In Australia, interest has soared regarding Atomo's COVID-19 rapid tests. The company has engaged with the Australian Aged Care market to develop its first aged care COVID-19 rapid antigen screening program.

Atomo share price summary

Despite the positive turn of events, Atomo shares have gradually trekked lower in the past 12 months, posting a 44% loss. In 2021 alone, the company's share price is down around 30%.

Atomo has a market capitalisation of roughly $87.8 million, with more than 408 million shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Farmer with arms folded looking ahead.
Broker Notes

What is Morgans' view on GrainCorp shares after monster sell-off?

Is it time to buy-low after the sell-off?

Read more »

Person handing out $50 notes, symbolising ex-dividend date.
Dividend Investing

Where I'd invest $10,000 into ASX dividend shares right now

I think these businesses are a strong buy for passive income.

Read more »

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Market News

Why Aeris Resources, Netwealth, Nova Minerals, and Paragon Care shares are dropping today

These shares are under pressure on Friday. Let's find out why.

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

A man leans forward over his phone in his hands with a satisfied smirk on his face although he has just learned something pleasing or received some satisfying news.
Share Market News

Downer EDI wins $870m NZ highway maintenance contracts: What investors need to know

Downer EDI wins major New Zealand state highway maintenance contracts worth NZ$870 million, expanding its infrastructure portfolio.

Read more »